Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Neurocrine Biosciences Inc (NASDAQ:NBIX)

51.78
Delayed Data
As of Apr 24
 +0.68 / +1.33%
Today’s Change
37.35
Today|||52-Week Range
55.15
+33.80%
Year-to-Date
Should You Make a Bet on the Healthcare Stocks?
Apr 18 / Zacks.com - Paid Partner Content
Here's Why Neurocrine (NBIX) Stock is Soaring 24% Today
Apr 12 / Zacks.com - Paid Partner Content
Neurocrine's Stock Up, FDA Nod for Tardive Dyskinesia Drug
Apr 13 / Zacks.com - Paid Partner Content
Repros' Proellex Continues to be Under Partial Clinical Hold
Apr 11 / Zacks.com - Paid Partner Content
Company News for April 13, 2017
Apr 13 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close51.10
Today’s open51.69
Day’s range51.34 - 52.18
Volume932,120
Average volume (3 months)1,247,861
Market cap$4.5B
Dividend yield--
Data as of 04/24/2017

Growth & Valuation

Earnings growth (last year)-55.24%
Earnings growth (this year)-39.98%
Earnings growth (next 5 years)-32.75%
Revenue growth (last year)-24.12%
P/E ratioNM
Price/Sales223.72
Price/Book14.10

Competitors

 Today’s
change
Today’s
% change
KITEKite Pharma Inc+2.75+3.46%
TECHBio-Techne Corp+1.38+1.35%
BLUEbluebird bio Inc+3.25+3.94%
NKTRNektar Therapeutics+0.49+2.67%
Data as of 04/24/2017

Financials

Next reporting dateMay 4, 2017
EPS forecast (this quarter)-$0.74
Annual revenue (last year)$15.0M
Annual profit (last year)-$141.1M
Net profit margin-940.60%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
Kevin Charles Gorman
President, Chief Operating &
Financial Officer
David-Alexandre C. Gros
Corporate headquarters
San Diego, California

Forecasts


Search for Jobs